Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cassava Sciences Inc (NQ: SAVA )

21.99 -0.06 (-0.27%)
Streaming Delayed Price Updated: 10:33 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS... 
Via Benzinga
How Is The Market Feeling About Cassava Sciences Inc?
Cassava Sciences Inc's (NASDAQ:SAVA) short percent of float has fallen 3.25% since its last report. The company recently reported that it has 10.93 million shares sold short,... 
Via Benzinga
Cassava Sciences Is Worth Considering After Hitting Its Latest Trough
The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult. 
Via InvestorPlace
Dear SOFI Stock Fans, Mark Your Calendars for May 1
SoFi Technologies (SOFI) stock is slipping on Tuesday and may see further falls this week ahead of student loan moratorium news. 
Via InvestorPlace
This Is What Whales Are Betting On Cassava Sciences
A whale with a lot of money to spend has taken a noticeably bullish stance on Cassava Sciences. Looking at options history for Cassava Sciences (NASDAQ:SAVA) we detected 14 strange trades. 
Via Benzinga
Keep an Eye on $60 as a Target Price for Cassava Sciences
As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. 
Via InvestorPlace
This Is What Whales Are Betting On Cassava Sciences
Someone with a lot of money to spend has taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are... 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Down Today?
Cassava Sciences (SAVA) stock is falling on Tuesday as investors react to a recent fireside chat held by CEO Remi Barbier. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 29.74% on an annualized basis producing an average annual return of 43.85%. Currently, Cassava Sciences has a market... 
Via Benzinga
Risk-on Biotech Investors Should Buy Cassava Sciences
SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch. 
Via InvestorPlace
Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 26.48% on an annualized basis. Buying $100 In SAVA: 5 years ago, an investor could have... 
Via Benzinga
Keep Risk in Mind With Cassava Sciences Stock, but Don’t Dismiss Upside Potential
A recent admission by management underscores the need to make SAVA stock, at best, a small, speculative position in your portfolio. 
Via InvestorPlace
Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days
SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Eargo (NASDAQ:EAR) shares rose 10.... 
Via Benzinga
Why Cassava Sciences Is Still a High-Risk Play
As it's not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously. 
Via InvestorPlace
23 Stocks Moving in Wednesday's Pre-Market Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 64.9% to $2.54 in pre-market trading after gaining around 5% on Tuesday. Roth Capital recently initiated coverage on the... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Check Out What Whales Are Doing With SAVA
Someone with a lot of money to spend has taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For Feb. 11, 2022: Cassava Sciences, Cleveland Cliffs, GameStop, and More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago, Would Be Worth This Much
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 53.42% on an annualized basis. 
Via Benzinga
Cassava Sciences Whale Trades Spotted
Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Does Cassava Sciences and Its Alzheimer’s Drug Really Have What It Takes?
Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows. SAVA stock is pure speculation either way. 
Via InvestorPlace
5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR Inc, Biofrontera And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.... 
Via Benzinga
The End Result May Be Worth the Wait With Cassava Sciences Stock
SAVA stock will continue to trade sideways until the moment of truth arrives for its drug candidate Simufilam. 
Via InvestorPlace
Short Squeeze Activity: New Players, Same Game, Different Results
Short squeezes will remain a big story in the financial news media until heavily shorted stocks that have been pushed up by individual investors come crashing back to earth. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade
Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. 
Via InvestorPlace
Cassava Sciences Stock Is Still Risky but Has Plenty of Upside Potential
Among the plethora of high-risk, speculative, clinical-stage biotech plays out there, SAVA stock is one of the better bets out there. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.